RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis
FRA:RHK - Deutsche Boerse Ag - DE0007042301 - Common Stock - Currency: EUR
Taking everything into account, RHK scores 5 out of 10 in our fundamental rating. RHK was compared to 25 industry peers in the Health Care Providers & Services industry. While RHK has a great health rating, its profitability is only average at the moment. RHK is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RHK had positive earnings in the past year.
RHK had a positive operating cash flow in the past year.
Each year in the past 5 years RHK has been profitable.
In the past 5 years RHK always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of RHK (2.34%) is comparable to the rest of the industry.
RHK has a worse Return On Equity (3.35%) than 64.00% of its industry peers.
RHK's Return On Invested Capital of 2.75% is on the low side compared to the rest of the industry. RHK is outperformed by 64.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for RHK is below the industry average of 6.33%.
The last Return On Invested Capital (2.75%) for RHK is above the 3 year average (2.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.34% | ||
| ROE | 3.35% | ||
| ROIC | 2.75% |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
1.3 Margins
Looking at the Profit Margin, with a value of 2.72%, RHK is in line with its industry, outperforming 44.00% of the companies in the same industry.
RHK's Profit Margin has declined in the last couple of years.
RHK has a worse Operating Margin (3.04%) than 64.00% of its industry peers.
RHK's Operating Margin has declined in the last couple of years.
RHK has a Gross Margin of 66.44%. This is in the better half of the industry: RHK outperforms 68.00% of its industry peers.
RHK's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.04% | ||
| PM (TTM) | 2.72% | ||
| GM | 66.44% |
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RHK is destroying value.
The number of shares outstanding for RHK remains at a similar level compared to 1 year ago.
RHK has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for RHK has been reduced compared to a year ago.
2.2 Solvency
RHK has an Altman-Z score of 3.04. This indicates that RHK is financially healthy and has little risk of bankruptcy at the moment.
RHK has a Altman-Z score of 3.04. This is amongst the best in the industry. RHK outperforms 92.00% of its industry peers.
The Debt to FCF ratio of RHK is 2.62, which is a good value as it means it would take RHK, 2.62 years of fcf income to pay off all of its debts.
RHK has a better Debt to FCF ratio (2.62) than 92.00% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that RHK is not too dependend on debt financing.
RHK's Debt to Equity ratio of 0.09 is amongst the best of the industry. RHK outperforms 96.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.62 | ||
| Altman-Z | 3.04 |
ROIC/WACC0.43
WACC6.35%
2.3 Liquidity
A Current Ratio of 2.23 indicates that RHK has no problem at all paying its short term obligations.
RHK has a better Current ratio (2.23) than 92.00% of its industry peers.
RHK has a Quick Ratio of 2.14. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
RHK has a Quick ratio of 2.14. This is amongst the best in the industry. RHK outperforms 92.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.23 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
The earnings per share for RHK have decreased by -7.07% in the last year.
The Earnings Per Share has been growing slightly by 0.03% on average over the past years.
RHK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.58%.
RHK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.12% yearly.
EPS 1Y (TTM)-7.07%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%-31.25%
Revenue 1Y (TTM)9.58%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.34%
3.2 Future
Based on estimates for the next years, RHK will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.28% on average per year.
Based on estimates for the next years, RHK will show a small growth in Revenue. The Revenue will grow by 5.94% on average per year.
EPS Next Y11.29%
EPS Next 2Y10.72%
EPS Next 3Y10.65%
EPS Next 5Y12.28%
Revenue Next Year8.14%
Revenue Next 2Y6.08%
Revenue Next 3Y5.77%
Revenue Next 5Y5.94%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 21.33, RHK is valued on the expensive side.
Based on the Price/Earnings ratio, RHK is valued a bit more expensive than the industry average as 60.00% of the companies are valued more cheaply.
RHK's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.17.
Based on the Price/Forward Earnings ratio of 16.68, the valuation of RHK can be described as correct.
The rest of the industry has a similar Price/Forward Earnings ratio as RHK.
RHK's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.33 | ||
| Fwd PE | 16.68 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, RHK is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
RHK's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.98 | ||
| EV/EBITDA | 0.52 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RHK does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)1.89
PEG (5Y)627.34
EPS Next 2Y10.72%
EPS Next 3Y10.65%
5. Dividend
5.1 Amount
With a yearly dividend of 0.78%, RHK is not a good candidate for dividend investing.
RHK's Dividend Yield is comparable with the industry average which is at 2.77.
With a Dividend Yield of 0.78, RHK pays less dividend than the S&P500 average, which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.78% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DP0%
EPS Next 2Y10.72%
EPS Next 3Y10.65%
FRA:RHK (5/28/2025, 7:00:00 PM)
12.8
+0.1 (+0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.69%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap857.09M
Analysts45.71
Price Target14.28 (11.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.78% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.33 | ||
| Fwd PE | 16.68 | ||
| P/S | 0.54 | ||
| P/FCF | 14.98 | ||
| P/OCF | 6.72 | ||
| P/B | 0.66 | ||
| P/tB | 0.76 | ||
| EV/EBITDA | 0.52 |
EPS(TTM)0.6
EY4.69%
EPS(NY)0.77
Fwd EY6%
FCF(TTM)0.85
FCFY6.67%
OCF(TTM)1.91
OCFY14.89%
SpS23.83
BVpS19.35
TBVpS16.76
PEG (NY)1.89
PEG (5Y)627.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.34% | ||
| ROE | 3.35% | ||
| ROCE | 3.34% | ||
| ROIC | 2.75% | ||
| ROICexc | 4.77% | ||
| ROICexgc | 6.01% | ||
| OM | 3.04% | ||
| PM (TTM) | 2.72% | ||
| GM | 66.44% | ||
| FCFM | 3.58% |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexcg growth 3Y17.7%
ROICexcg growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.62 | ||
| Debt/EBITDA | 1.04 | ||
| Cap/Depr | 112.46% | ||
| Cap/Sales | 4.41% | ||
| Interest Coverage | 15.15 | ||
| Cash Conversion | 114.87% | ||
| Profit Quality | 131.95% | ||
| Current Ratio | 2.23 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | 3.04 |
F-Score6
WACC6.35%
ROIC/WACC0.43
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.07%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%-31.25%
EPS Next Y11.29%
EPS Next 2Y10.72%
EPS Next 3Y10.65%
EPS Next 5Y12.28%
Revenue 1Y (TTM)9.58%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.34%
Revenue Next Year8.14%
Revenue Next 2Y6.08%
Revenue Next 3Y5.77%
Revenue Next 5Y5.94%
EBIT growth 1Y18.95%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year145.13%
EBIT Next 3Y44.3%
EBIT Next 5Y34.88%
FCF growth 1Y23.81%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y17.06%
OCF growth 3Y9.38%
OCF growth 5Y21.95%